Lakefront Biotherapeutics (LKFT) Change in Working Capital (2017 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Change in Working Capital for 9 consecutive years, with -$14.0 million the latest figure, recorded in Q1 2026.

• Quarterly Change in Working Capital rose 11.08% year-over-year to -$14.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$70.5 million (up 27.34% YoY) and the FY2020 annual result came in at $4.6 million, up 152.61% from the prior year.
• Change in Working Capital declined to -$14.0 million in Q1 2026 per LKFT's latest filing, from -$9.6 million in the prior quarter.
• Over the last five years, Change in Working Capital for LKFT reached as high as $3.6 million in Q1 2022 and fell as low as -$41.5 million in Q2 2024.
• A 5-year average of -$17.7 million and a median of -$14.0 million in 2026 frame the typical range for Change in Working Capital.
• Annual changes were most pronounced in 2023 — Change in Working Capital slumped 419.1% — and 2025, when it surged 46.19%.
• Year by year, Change in Working Capital stood at $3.6 million in 2022, then plunged by 419.1% to -$11.3 million in 2023, then advanced by 5.23% to -$10.8 million in 2024, then advanced by 11.13% to -$9.6 million in 2025, then sank by 46.08% to -$14.0 million in 2026.
• According to Business Quant data, Change in Working Capital over the past three periods registered -$14.0 million, -$9.6 million, and -$31.3 million for Q1 2026, Q3 2025, and Q2 2025 respectively.